Ірландія - англійська - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - granisetron hydrochloride - concentrate for solution for injection - 1 milligram(s)/millilitre - serotonin (5ht3) antagonists

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

silver pharma s.l. - mercaptopurine - tablet - 50 milligram(s) - mercaptopurine

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.1 mg (equivalent: pemetrexed, qty 500 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 1208.21 mg (equivalent: pemetrexed, qty 1000 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.82 mg (equivalent: pemetrexed, qty 100 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

the premier pharmaceutical co ltd - liquid - each 5 ml mixture contains potassium bicarbonate 200 mg potassium citrate 600 mg

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - memantine hydrochloride 10mg; memantine hydrochloride 10mg - film coated tablet - 10 mg - active: memantine hydrochloride 10mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate methacrylic acid - ethyl acrylate copolymer microcrystalline cellulose polysorbate 80 purified talc   purified water simeticone sodium laurilsulfate triacetin active: memantine hydrochloride 10mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide - treatment of patients with moderate to severe alzheimer's disease

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - mercaptopurine monohydrate 50mg; mercaptopurine monohydrate 50mg - tablet - 50 mg - active: mercaptopurine monohydrate 50mg excipient: lactose monohydrate magnesium stearate maize starch stearic acid active: mercaptopurine monohydrate 50mg excipient: lactose monohydrate magnesium stearate maize starch stearic acid - puri-nethol is indicated for the treatment of acute leukaemia. it may be utilised in remission induction and is particularly indicated for maintenance therapy in: · acute lymphoblastic leukaemia; · acute myelogenous leukaemia.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 8 mg/ml - solution for injection - 8 mg/ml - active: somatropin 8 mg/ml excipient: citric acid phenol poloxamer sodium hydroxide sucrose water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).